SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
GENERAL ATLANTIC GENPAR (BERMUDA), L.P.

(Last) (First) (Middle)
C/O CONYERS CLIENT SERVICES LIMITED
CLARENDON HOUSE, 2 CHURCH STREET

(Street)
HAMILTON D0 HM11

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CinCor Pharma, Inc. [ CINC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/11/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.00001 per share ("Common Stock") 01/11/2022 C(1) 2,426,470 A (1) 2,426,470 I See footnote(2)(3)(4)
Common Stock 01/11/2022 P(5) 1,700,000 A $16 4,126,470 I See footnote(2)(3)(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series B Preferred Stock (1) 01/11/2022 C 8,250,000 (1) (1) Common stock 2,426,470 (1) 0 I See footnote(2)(3)(4)
1. Name and Address of Reporting Person*
GENERAL ATLANTIC GENPAR (BERMUDA), L.P.

(Last) (First) (Middle)
C/O CONYERS CLIENT SERVICES LIMITED
CLARENDON HOUSE, 2 CHURCH STREET

(Street)
HAMILTON D0 HM11

(City) (State) (Zip)
1. Name and Address of Reporting Person*
GAP (Bermuda) L.P.

(Last) (First) (Middle)
C/O CONYERS CLIENT SERVICES LIMITED
CLARENDON HOUSE, 2 CHURCH STREET

(Street)
HAMILTON D0 HM11

(City) (State) (Zip)
1. Name and Address of Reporting Person*
GAP Coinvestments CDA, L.P.

(Last) (First) (Middle)
C/O GENERAL ATLANTIC SERVICE CO.,L.P.
55 EAST 52ND STREET, 33RD FLOOR

(Street)
NEW YORK NY 10055

(City) (State) (Zip)
1. Name and Address of Reporting Person*
General Atlantic (CIN), L.P.

(Last) (First) (Middle)
C/O GENERAL ATLANTIC SERVICE CO.,L.P.
55 EAST 52ND STREET, 33RD FLOOR

(Street)
NEW YORK NY 10055

(City) (State) (Zip)
1. Name and Address of Reporting Person*
General Atlantic (SPV) GP, LLC

(Last) (First) (Middle)
C/O GENERAL ATLANTIC SERVICE CO.,L.P.
55 EAST 52ND ST. 32ND FLOOR

(Street)
NEW YORK NY 10055

(City) (State) (Zip)
Explanation of Responses:
1. Represents the automatic conversion of Series B Preferred Stock into shares of Common Stock of CinCor Pharma, Inc. (" the Issuer"), on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering (the "IPO") which closed on January 11, 2022.
2. Reflects securities held directly by General Atlantic (CIN), L.P. ("GA CIN"), a Delaware limited partnership. The limited partners of GA CIN are the following investment funds (the "GA Funds"): General Atlantic Partners 100, L.P., a Delaware limited partnership ("GAP 100"), General Atlantic Partners (Bermuda) EU, L.P., a Bermuda limited partnership ("GAP Bermuda EU"), General Atlantic Partners (Lux) SCSp, a Luxembourg special limited partnership ("GAP Lux"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), and GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V").
3. The general partner of GA (CIN) is General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"). The general partner of GAP Lux is General Atlantic GenPar, (Lux) SCSp, a Luxembourg special limited partnership ("GA GenPar Lux") and the general partner of GA GenPar Lux is General Atlantic (Lux) S.a.r.l., a Luxembourg company ("GA Lux"). The general partner of GAP Bermuda EU and the sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P., a Bermuda limited partnership ("GenPar Bermuda"). GAP (Bermuda) L.P. ("GAP (Bermuda) LP") is the general partner of GenPar Bermuda.
4. The general partner of GAP 100 is General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"). General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. There are nine members of the management committee of GA LP (the "GA Management Committee"). The members of the GA Management Committee are also the members of the management committee of GAP (Bermuda) LP. Each of the members of the GA Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein.
5. The shares of Common Stock were purchased by GA CIN in the Issuer's IPO which closed on January 11, 2022, at a price of $16.00.
Remarks:
GA CIN, the GA Funds, GA SPV, GA GenPar Lux, GA Lux, GenPar Bermuda, GAP (Bermuda) LP, GA GenPar, and GA LP may be deemed to be members of a "group" for the purposes of the Securities Exchange Act of 1934. Each reporting person disclaims beneficial ownership of any securities deemed to be owned by the group that are not directly owned by the reporting person. This report shall not be deemed an admission that the reporting persons are a member of a group or the beneficial owner of any securities not directly owned by the reporting person. // Form 2 of 2.
/s/ Michael Gosk 01/13/2022
/s/ Michael Gosk 01/13/2022
/s/ Michael Gosk 01/13/2022
/s/ Michael Gosk 01/13/2022
/s/ Michael Gosk 01/13/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.